

Datasheet for ABIN6253540

**CD96 Protein (CD96) (AA 22-503) (Fc Tag)**[Go to Product page](#)**2** Images

## Overview

Quantity:	100 µg
Target:	CD96
Protein Characteristics:	AA 22-503
Origin:	Human
Source:	HEK-293 Cells
Protein Type:	Recombinant
Biological Activity:	Active
Purification tag / Conjugate:	This CD96 protein is labelled with Fc Tag.

## Product Details

Sequence:	AA 22-503
Characteristics:	This protein carries a mouse IgG2a Fc tag at the C-terminus. The protein has a calculated MW of 80.6 kDa. The protein migrates as 32 KDa, 34 KDa and 120 KDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Purity:	>90 % as determined by reduced SDS-PAGE.
Endotoxin Level:	Less than 0.1 EU per µg by the LAL method.

## Target Details

Target:	CD96
Alternative Name:	CD96 ( <a href="#">CD96 Products</a> )

## Target Details

**Background:** The progression of pancreatic cancer (PC) is significantly associated with tumor immune escape, which may be associated with nature killer (NK) cell dysfunction. CD226, CD96, and TIGIT, which share the ligand CD155, play important roles in the regulation of NK cell function. The present study was conducted to investigate the roles of these molecules in NK cells from PC patients. TIGIT and CD96 together with the co-stimulatory receptor CD226 form a pathway that is analogous to the CD28/CTLA-4 pathway, in which shared ligands and differential receptor:ligand affinities fine-tune the immune response. Although the roles of TIGIT and CD96 as immune checkpoint receptors in T cell and natural killer cell biology are just beginning to be uncovered, accumulating data support the targeting of these receptors for improving anti-tumor immune responses. A clear understanding of the immune cell populations regulated by TIGIT and CD96 is key to the design of immunotherapies that target these receptors in combination with other existing immune checkpoint blockade therapies. The dysfunction of CD96 may trigger C syndrome: A syndrome characterized by trigonocephaly, severe mental retardation, hypotonia, variable cardiac defects, redundant skin, and dysmorphic facial features, including upslanted palpebral fissures, epicanthal folds, depressed nasal bridge, and low-set, posteriorly rotated ears.

**Molecular Weight:** 80.4 kDa

**NCBI Accession:** [NP\\_005807](#)

## Application Details

**Restrictions:** For Research Use only


## Handling

**Format:** Lyophilized

**Buffer:** Tris with Glycine, Arginine and NaCl, pH 7.5


**Handling Advice:** Please avoid repeated freeze-thaw cycles.

**Storage:** -20 °C



SDS-PAGE

**Image 1.** Human CD96, Mouse IgG2a Fc Tag, low endotoxin on under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90 % .



ELISA

**Image 2.** Immobilized Human CD96, Mouse IgG2a Fc Tag, low endotoxin (ABIN5674625,ABIN6253540) at 2 µg/mL (100 µL/well) can bind Human CD155, Fc Tag (ABIN2870620,ABIN2870621) with a linear range of 20-312 ng/mL (QC tested).